Overview

* Fortrea Q2 2025 revenue of $710.3 mln beats analyst expectations

* Adjusted EBITDA of $54.9 mln exceeds estimates, per LSEG data

* Company raises 2025 revenue guidance to $2.6 bln-$2.7 bln

Outlook

* Fortrea ( FTRE ) raises 2025 revenue guidance to $2,600 mln-$2,700 mln

* Company affirms 2025 adjusted EBITDA guidance of $170 mln-$200 mln

* Fortrea ( FTRE ) assumes stable foreign exchange rates for 2025 forecast

Result Drivers

* GOODWILL IMPAIRMENT - Net loss impacted by $309.1 mln non-cash goodwill impairment charge

* COST SAVINGS - Cost saving initiatives remain on track, contributing to operational commitments

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $710.30 $629.40

Revenue mln mln (9

Analysts

)

Q2 EPS -$4.14

Q2 Net -$374.90

Income mln

Q2 Beat $54.90 $39.20

Adjusted mln mln (9

EBITDA Analysts

)

Q2 -$330.30

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 8 "hold" and 2 "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy."

* Wall Street's median 12-month price target for Fortrea Holdings Inc ( FTRE ) is $5.50, about 19.3% below its August 5 closing price of $6.56

* The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 11 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)